Vivoryon - Pivoting to Kidney Disease
Vivoryon recently provided a strategic update for varo’, which failed to show a clinical benefit in mild Alzheimer’s disease. A pre-specified analysis of varo’ on kidney function biomarkers showed statistically significant improvements. The eGFR data collected over two years suggests that varo’ could have potentially superior beneficial effects on the kidney than the standard of care drugs (SGLT-2s) in CKD, in our view, though further development would be required to confirm this. Consequently, VVY will evaluate the potential of varo’ and other QPCT/L inhibitors in kidney disease, with the next step being a decision on a clinical programme to pursue.For access to the full note, please contact Naresh Chouhan ( )
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.